drugset / Trial / NCT06310551
First Time in Human Study of Long Acting VH4524184 Formulations
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to identify 1 or more doses of parenterally administered VH4524184 that are safe, well tolerated and yield a PK drug exposure profile necessary to deliver a long-acting antiretroviral therapy for the treatment of HIV-1 infection.
Timeline
- Start
- 2024-03-21
- Primary completion
- 2028-01-21
- Completion
- 2028-01-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VH4524184 | Unknown | — | Oral |
| Background | rHuPH20 | Protein / enzyme biologic | — | Subcutaneous |